. 2021 Nov 29;13(23):6017. doi: 10.3390/cancers13236017

Table 5.

Univariate analysis of progression-free survival (PFS) from 1st to 4th treatment line and of the study cohort, based on serum free light chain values.

Category		n.	Median PFS1, Months (95% CI)	p	n.	Median PFS2, Months (95% CI)	p	n.	Median PFS3, Months (95% CI)	p	n.	Median PFS4, Months (95% CI)	p	n.	Cohort’s Median PFS, Months (95% CI)	p
Involved pre–FLC	<138 mg/mL	9	21 (2–28)	0.59	14	11 (6–19)	0.34	33	20 (7–23)	0.0002	25	10 (7–19)	0.03	82	13 (10–20)	0.0086
Involved pre–FLC	≥138 mg/mL	19	16 (8–29)	0.59	27	10 (8–20)	0.34	38	6 (5–8)	0.0002	30	7 (5–12)	0.03	113	8 (7–10)	0.0086
Pre–FLCr	<25	10	21 (2–28)	0.98	23	14 (8–19)	0.71	39	17 (7–23)	0.0009	33	9 (7–15)	0.33	105	13 (9–17)	0.0065
Pre–FLCr	≥25	18	14 (6–26)	0.98	18	8 (4–19)	0.71	32	6 (5–8)	0.0009	22	7 (5–12)	0.33	90	8 (6–10)	0.0065
Involved post–FLC	<138 mg/mL	14	28 (13–45)	0.46	33	20 (10–29)	0.16	26	15 (6–22)	0.059	19	11 (6–15)	0.13	93	16 (11–22)	0.014
Involved post–FLC	≥138 mg/mL	27	24 (11–29)	0.46	38	15 (10–24)	0.16	42	7 (6–10)	0.059	30	7 (5–9)	0.13	136	11 (8–14)	0.014
Post–FLCr	<25	23	28 (21–35)	0.8	39	20 (11–29)	0.13	36	11 (7–20)	0.03	26	11 (7–15)	0.01	124	16 (12–20)	0.0079
Post–FLCr	≥25	18	18 (8–27)	0.8	32	14 (9–24)	0.13	32	6 (5–10)	0.03	23	7 (5–8)	0.01	105	11 (7–13)	0.0079

Abbreviations: n.—number of patients; CI—confidence interval; p—p value; PFS—progression free survival; Involved pre-FLC—involved serum free light chains prior to treatment start; Pre-FLCr—serum free light chains ratio prior to treatment start; Involved post-FLC—involved serum free light chains at disease relapse following last therapy; Post-FLCr—serum free light chains ratio at disease relapse following last therapy.